$ACHV
ACHIEVE LIFE SCIENCES, INC.

2022 Q1 Form 10-Q Financial Statement

#000156459022019876 Filed on May 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.838M $2.340M
YoY Change 21.28% 28.57%
% of Gross Profit
Research & Development $4.388M $5.642M
YoY Change -22.23% 266.13%
% of Gross Profit
Depreciation & Amortization $60.00K $60.00K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $7.226M $5.642M
YoY Change 28.08% 266.13%
Operating Profit
YoY Change
Interest Expense $357.0K $10.00K
YoY Change 3470.0% -75.0%
% of Operating Profit
Other Income/Expense, Net $6.000K -$15.00K
YoY Change -140.0% -140.54%
Pretax Income -$7.573M -$8.000M
YoY Change -5.34% 140.96%
Income Tax
% Of Pretax Income
Net Earnings -$7.573M -$7.999M
YoY Change -5.33% 140.93%
Net Earnings / Revenue
Basic Earnings Per Share -$0.80
Diluted Earnings Per Share -$800.6K -$1.305M
COMMON SHARES
Basic Shares Outstanding 9.459M
Diluted Shares Outstanding 9.459M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.34M $29.60M
YoY Change 22.76% 142.62%
Cash & Equivalents $36.30M $29.69M
Short-Term Investments
Other Short-Term Assets $1.355M $800.0K
YoY Change 69.38% 14.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $37.69M $30.44M
YoY Change 23.83% 135.96%
LONG-TERM ASSETS
Property, Plant & Equipment $49.00K $33.00K
YoY Change 48.48% -89.0%
Goodwill $1.034M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $253.0K $200.0K
YoY Change 26.5% -33.33%
Total Long-Term Assets $2.922M $3.261M
YoY Change -10.4% -11.86%
TOTAL ASSETS
Total Short-Term Assets $37.69M $30.44M
Total Long-Term Assets $2.922M $3.261M
Total Assets $40.61M $33.70M
YoY Change 20.52% 103.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $418.0K $600.0K
YoY Change -30.33% 200.0%
Accrued Expenses $3.592M $2.900M
YoY Change 23.86% 107.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.010M $3.500M
YoY Change 14.57% 133.33%
LONG-TERM LIABILITIES
Long-Term Debt $15.17M $0.00
YoY Change
Other Long-Term Liabilities $0.00 $100.0K
YoY Change -100.0% 0.0%
Total Long-Term Liabilities $15.17M $100.0K
YoY Change 15071.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.010M $3.500M
Total Long-Term Liabilities $15.17M $100.0K
Total Liabilities $19.18M $3.574M
YoY Change 436.68% 110.24%
SHAREHOLDERS EQUITY
Retained Earnings -$101.2M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.43M $30.09M
YoY Change
Total Liabilities & Shareholders Equity $40.61M $33.70M
YoY Change 20.52% 102.44%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$7.573M -$7.999M
YoY Change -5.33% 140.93%
Depreciation, Depletion And Amortization $60.00K $60.00K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$6.800M -$6.452M
YoY Change 5.39% 44.63%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 95.00K 236.0K
YoY Change -59.75% -602.13%
NET CHANGE
Cash From Operating Activities -6.800M -6.452M
Cash From Investing Activities 0.000
Cash From Financing Activities 95.00K 236.0K
Net Change In Cash -6.685M -6.216M
YoY Change 7.55% 37.89%
FREE CASH FLOW
Cash From Operating Activities -$6.800M -$6.452M
Capital Expenditures $0.00
Free Cash Flow -$6.452M
YoY Change 44.57%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3D
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
49000
CY2022Q1 achv Other Assets And Restricted Cash
OtherAssetsAndRestrictedCash
253000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1586000
CY2022Q1 us-gaap Goodwill
Goodwill
1034000
CY2022Q1 us-gaap Assets
Assets
40614000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
418000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
648000
CY2022Q1 achv Accrued Liabilities Clinical Current
AccruedLiabilitiesClinicalCurrent
2222000
CY2022Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
663000
CY2022Q1 achv Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
-1000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
542000
CY2022Q1 achv Shares Issued As Settlement With Trade Vendor As Non Monetary Transaction
SharesIssuedAsSettlementWithTradeVendorAsNonMonetaryTransaction
26000
CY2021Q1 achv Shares Issued As Settlement With Trade Vendor As Non Monetary Transaction
SharesIssuedAsSettlementWithTradeVendorAsNonMonetaryTransaction
23000
CY2022Q1 achv Accrued Interest On Svb Convertible Debt
AccruedInterestOnSVBConvertibleDebt
-271000
CY2022Q1 achv Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-153000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
59000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4010000
CY2022Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
15171000
CY2022Q1 us-gaap Interest Expense
InterestExpense
357000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-7999000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
64000
CY2022Q1 achv Increase Decrease In Accrued Clinical Liabilities
IncreaseDecreaseInAccruedClinicalLiabilities
870000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6779000
CY2022Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
24000
CY2021Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
236000
CY2022Q1 achv Proceeds From At Market Offering
ProceedsFromAtMarketOffering
91000
CY2022Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
20000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
95000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
236000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6685000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6216000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36387000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29687000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
28042000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
823000
CY2022Q1 achv Shares Issued On Exercise Of Warrants Value
SharesIssuedOnExerciseOfWarrantsValue
24000
CY2022Q1 achv Adjustments To Additional Paid In Capital Shares Issued Through At The Market Offering
AdjustmentsToAdditionalPaidInCapitalSharesIssuedThroughAtTheMarketOffering
91000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
26000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7573000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
37286000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
542000
CY2021Q1 achv Shares Issued On Exercise Of Warrants Value
SharesIssuedOnExerciseOfWarrantsValue
236000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
23000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-7999000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
30088000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-101200000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36300000
CY2022Q1 achv Working Capital Balance
WorkingCapitalBalance
33700000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-7600000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6800000
CY2015Q2 us-gaap Finite Lived Intangible Assets Fair Value Disclosure
FiniteLivedIntangibleAssetsFairValueDisclosure
3100000
CY2015Q2 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P14Y
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
167000
CY2022Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
223000
CY2022Q1 achv Finite Lived Intangible Assets Amortization Expense After Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearTwo
973000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1586000
CY2022Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
34163000
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
34163000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2022Q1 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
50000
CY2022Q1 achv Maximum Maturity Period Of Cash And Cash Equivalents
MaximumMaturityPeriodOfCashAndCashEquivalents
P90D
CY2022Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2022Q1 us-gaap Convertible Debt
ConvertibleDebt
15171000
CY2022Q1 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
15547000
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2021Q4 us-gaap Convertible Debt
ConvertibleDebt
14920000
CY2021Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
15204000
CY2021Q4 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0225
CY2021Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.070
CY2022Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
15000000
CY2022Q1 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
117000
CY2021Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
109000
CY2022Q1 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
288000
CY2021Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
29000
CY2022Q1 us-gaap Convertible Debt
ConvertibleDebt
15171000
CY2021Q4 us-gaap Convertible Debt
ConvertibleDebt
14920000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
CY2022Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
267850
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.05
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
789940
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.98
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0149
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0059
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.2335
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.0987
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
13000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
38000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y9M29D
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M29D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0997
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0997
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
542000
CY2022Q1 us-gaap Contractual Obligation
ContractualObligation
58000
CY2022Q1 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
58000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
33000
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
42000
CY2022Q1 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2022Q1 achv Indemnification Expense
IndemnificationExpense
0

Files In Submission

Name View Source Status
0001564590-22-019876-index-headers.html Edgar Link pending
0001564590-22-019876-index.html Edgar Link pending
0001564590-22-019876.txt Edgar Link pending
0001564590-22-019876-xbrl.zip Edgar Link pending
achv-10q_20220331.htm Edgar Link pending
achv-10q_20220331_htm.xml Edgar Link completed
achv-20220331.xsd Edgar Link pending
achv-20220331_cal.xml Edgar Link unprocessable
achv-20220331_def.xml Edgar Link unprocessable
achv-20220331_lab.xml Edgar Link unprocessable
achv-20220331_pre.xml Edgar Link unprocessable
achv-ex311_7.htm Edgar Link pending
achv-ex321_6.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending